Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: BMRN stock price vs FCPT: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at FCPT's multiple
Needs FCPT P/E.
Implied fair value · at BMRN's multiple
Needs BMRN P/E.
Metric by metric
Price unavailable
Where each company leads, and how wide the gap is.
Growth edge
Pricing power
Operating leverage
Lower is better
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: BMRN FY 2025 (ended Dec 31, 2025) · FCPT FY 2025 (ended Dec 31, 2025).
Trendline
Five fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
BIOMARIN PHARMACEUTICAL INC · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Four Corners Property Trust, Inc. · implied price per share
Five annual free-cash-flow observations are required for the filing-backed baseline.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Debt / equity
Total debt against shareholders' equity
0.08x
0.74x
Net debt / EBITDA
Leverage against operating earnings
-1.43x
5.28x
Cash and equivalents
Liquid reserves on the balance sheet
$1.31B
$12.14M
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
VERTEX PHARMACEUTICALS INC / MA
BMRN vs VRTX
ALNYLAM PHARMACEUTICALS, INC.
BMRN vs ALNY
Sarepta Therapeutics, Inc.
BMRN vs SRPT
REGENXBIO Inc.
BMRN vs RGNX
IONIS PHARMACEUTICALS INC
BMRN vs IONS
PTC THERAPEUTICS, INC.
BMRN vs PTCT
REALTY INCOME CORP
BMRN vs O
AGREE REALTY CORP
BMRN vs ADC
GETTY REALTY CORP /MD/
BMRN vs GTY
ESSENTIAL PROPERTIES REALTY TRUST, INC.
BMRN vs EPRT
STAG Industrial, Inc.
BMRN vs STAG
$505.32M
$1.20B
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.
